E7-11907. Manufacturer of Controlled Substances; Notice of Registration

By Notice dated February 5, 2007, and published in the Federal Register on February 12, 2007, (72 FR 6579), Orasure Technologies, Inc., Lehigh University, Seeley G. Mudd-Building 6, 220 East First Street, Bethlehem, Pennsylvania 18015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Lysergic acid diethylamide (LSD) (7315)	I
4-Methoxyamphetamine (7411)	I
Normorphine (9313)	I
Tetrahydrocannabinols (THC) (7370)	I
Alphamethadol (9605)	I
Amphetamine (1100)	II
Methamphetamine (1105)	II
Cocaine (9041)	II
Hydromorphone (9150)	II
Benzoylecgonine (9180)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Oxycodone (9143)	II
Meperidine (9230)	II
Methadone (9250)	II
Oxymorphone (9652)	II

The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Orasure Technologies, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Orasure Technologies, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: June 7, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator,Office of Diversion Control, Drug Enforcement Administration.